Yes the figures are huge and because of that they also talk it down because otherwise it looks so stupid. There is big potential here.
some other costs are rebates to dermatologists to push the drug to clients. This happens in America.
sales team might have a commission component.
but as Matt said in the eureka report, biotechs are profitable. they have to be because of the risks involved. Brickell spent $160m getting this drug through trials. a lot of drugs don't make it through the trial process so that's a lot of wasted time and money. If you get one through you'd want to be getting paid for your efforts.
Bot Chart, page-7400
-
- There are more pages in this discussion • 6,858 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $660.6M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.5¢ | $1.005M | 2.782M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 533180 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 198135 | 9 |
View Market Depth
| Last trade - 12.11pm 19/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |